Catalyst Wire Dossier Catalyst Wire Dossier

Everolimus (RAD001)

everolimus · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for Everolimus (RAD001), covering 2011-08-19 to 2019-04-01. Get the full timeline:

Most recent: Clinical Trial Update: An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis [Phase 4]

See pricing